香港交易及結算所有限公司及香港聯合交易所有限公司對本通告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不就因本通告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 MicroPort CardioFlow Medtech Corporation 微創心通醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2160） 股東特別大會通告 茲通告微創心通醫療科技有限公司（「本公司」）謹訂於2025年12月15日（星期一）上 午十時正假座中國上海市浦東新區張江高科技園區牛頓路501號舉行股東特別大會（「股 東特別大會」），藉以處理下列事項。除另有界定者外，本通告所用詞彙與本公司日期 為2025年11月24日的通函所界定者具有相同涵義： 普通決議案 – 1 – 1. 「動議： (a) 謹此批准、追認及確認本公司、MicroPort CardioFlow CRM Limited（「合併附屬 公司」）及微創心律管理有限公司（「目標公司」）就（其中包括）目標公司及合併 附屬公司根據開曼《公司法》第233條的建議合併（「合併」）訂立的日期為 ...

此乃要件 請即處理 閣下如對本通函任何內容或應採取的行動有任何疑問，應諮詢 閣下的持牌證券交易商或註冊證券機構、銀行經理、律 師、專業會計師或其他專業顧問。 閣下如已出售或轉讓名下的微創心通醫療科技有限公司全部股份，應立即將本通函及隨附之委任代表表格送交買主或 承讓人，或送交經手買賣或轉讓的銀行、持牌證券交易商、註冊證券機構或其他代理商，以便轉交買主或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其準確性或完整性亦不發表任何 聲明，並明確表示，概不就因本通函全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 本通函僅供參考，並不構成收購、購買或認購微創心通醫療科技有限公司任何證券的邀請或要約。 MicroPort CardioFlow Medtech Corporation 微創心通醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2160） (1)非常重大收購事項及涉及就收購目標集團 而根據特別授權發行新股份的關連交易； 及 (2)股東特別大會通告 目標集團的獨家財務顧問 ® 獨立董事委員會及獨立股東的獨立 ...

Group 1 - Southbound funds reduced their holdings in HeartCare Medical-B (02160.HK) by 14,000 shares on November 13, 2025 [1] - Over the past 5 trading days, there has been a cumulative net reduction of 192,000 shares by southbound funds [1] - In the last 20 trading days, southbound funds have reduced their holdings for 20 days, totaling a net reduction of 1.733 million shares [1] Group 2 - As of now, southbound funds hold 110 million shares of HeartCare Medical-B, accounting for 4.55% of the company's total issued ordinary shares [1] - The company specializes in providing comprehensive medical solutions for structural heart disease, focusing on transcatheter and surgical solutions [2] - HeartCare Medical's product pipeline includes TAVI series products, AnchorMan left atrial appendage occluder products, transcatheter mitral valve products, transcatheter tricuspid valve products, and surgical support products [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 微创心通医疗科技有限公司 呈交日期: 2025年11月6日 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02160 | 說明 | | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 2,412,706,775 | | 0 | | 2,412,706,775 | | 增加 / 減少 (-) | | | | 0 | | 0 | | | | 本月底結存 | | | | 2,412,706,775 | | 0 | | 2,412,706,775 | 第 2 頁 共 10 頁 ...

Core Insights - Southbound funds reduced their holdings in HeartCare Medical-B (02160.HK) by 28,000 shares on November 4, 2025, marking a total net reduction of 596,000 shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have decreased their holdings by a total of 1,934,000 shares, indicating a consistent trend of selling [1] - As of now, southbound funds hold 110 million shares of HeartCare Medical-B, which represents 4.56% of the company's total issued ordinary shares [1] Trading Data Summary - On November 4, 2025, total shares held were 110 million, with a decrease of 28,000 shares, reflecting a change of -0.03% [2] - On November 3, 2025, total shares held remained at 110 million, with a decrease of 86,000 shares, reflecting a change of -0.08% [2] - On October 24, 2025, total shares held were 110 million, with a decrease of 109,000 shares, reflecting a change of -0.10% [2] - On October 21, 2025, total shares held were 111 million, with a decrease of 273,000 shares, reflecting a change of -0.25% [2] - On October 16, 2025, total shares held were 111 million, with a decrease of 100,000 shares, reflecting a change of -0.09% [2] Company Overview - HeartCare Medical Technology Co., Ltd. specializes in providing comprehensive medical solutions for treating structural heart diseases [2] - The company's main business involves the research and commercialization of transcatheter and surgical solutions in the field of structural heart disease [2] - The product pipeline includes transcatheter aortic valve implantation (TAVI) series products, AnchorMan left atrial appendage closure (LAAC) products, transcatheter mitral valve (TMV) products, transcatheter tricuspid valve (TTV) products, and surgical support products [2] - The company operates in both domestic and international markets [2]

Core Insights - Southbound funds reduced their holdings in HeartCare Medical-B (02160.HK) by 191,000 shares on October 15, 2025, marking a total net reduction of 856,000 shares over the past five trading days [1] - Over the last 20 trading days, southbound funds have consistently reduced their holdings, totaling a net decrease of 1,461,000 shares [1] - As of now, southbound funds hold 111 million shares of HeartCare Medical-B, representing 4.58% of the company's total issued ordinary shares [1] Company Overview - HeartCare Medical Technology Co., Ltd. specializes in providing comprehensive medical solutions for treating structural heart diseases [2] - The company's main business involves the research and commercialization of transcatheter and surgical solutions in the field of structural heart disease [2] - The product pipeline includes transcatheter aortic valve implantation (TAVI) series products, AnchorMan left atrial appendage closure (LAAC) products, transcatheter mitral valve (TMV) products, transcatheter tricuspid valve (TTV) products, and surgical accessory products [2] - The company operates in both domestic and international markets [2]

Core Insights - Southbound funds reduced their holdings in HeartCare Medical-B (02160.HK) by 223,000 shares on October 13, 2025, marking a continuous trend of selling over the past trading days [1] - Over the last 5 trading days, there has been a total net reduction of 724,000 shares, while in the last 20 trading days, the cumulative net reduction reached 1,385,000 shares [1] - As of now, southbound funds hold 111 million shares of HeartCare Medical-B, which represents 4.59% of the company's total issued ordinary shares [1] Company Overview - HeartCare Medical Technology Co., Ltd. specializes in providing comprehensive medical solutions for treating structural heart diseases [2] - The company's main business involves the research and commercialization of transcatheter and surgical solutions in the field of structural heart disease [2] - The product pipeline includes transcatheter aortic valve implantation (TAVI) series products, AnchorMan left atrial appendage closure (LAAC) products, transcatheter mitral valve (TMV) products, transcatheter tricuspid valve (TTV) products, and surgical support products [2] - The company operates in both domestic and international markets [2]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02160 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.000005 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 10,000,000,000 | USD | | 0.000005 USD | | 50,000 | 本月底法定/註冊股本總額： USD 50,000 FF301 截至月份: 2025年9月30日 狀態: 新提交 第 1 頁 共 10 頁 v 1.1.1 致：香港交易及結算所有限公司 公司名稱: 微创心通医疗 ...

Core Viewpoint - The announcement highlights the agreement between HeartLink Medical and MicroPort Cardiac Rhythm Management for a business integration, aiming to enhance their strategic positioning in the global cardiovascular market [1][2]. Group 1: Transaction Details - HeartLink Medical plans to acquire 100% of MicroPort Cardiac Rhythm Management for a valuation of $680 million, through a directed share issuance at a price of HKD 1.35 per share [1]. - The acquisition will be executed by issuing new shares to existing shareholders of MicroPort Cardiac Rhythm Management, including its parent company MicroPort Medical and investment firms such as Hillhouse Capital and Yunfeng Capital [1]. Group 2: Business Integration and Strategic Goals - The integration aims to combine the core businesses of cardiac rhythm management and structural heart disease, creating a more comprehensive cardiovascular treatment solution [2]. - The transaction is expected to generate synergies that will diversify and enhance HeartLink Medical's existing business, particularly in structural heart disease and CRM solutions, while improving R&D capabilities, production capacity, distribution channels, and market expansion [1][2]. Group 3: Conditions for Completion - The final implementation of the integration is subject to several closing conditions, including approval from HeartLink Medical's independent shareholders [3].

Core Viewpoint - Company plans to acquire MicroPort Cardiac Rhythm Management for a total consideration of 680 million USD, enhancing its global cardiac product platform [1] Group 1: Acquisition Details - The acquisition will involve the issuance of approximately 3.95 billion new shares at an issue price of 1.35 HKD per share [1] - MicroPort Cardiac Rhythm Management specializes in solutions for arrhythmia management, providing devices to monitor cardiac information [1] Group 2: Strategic Implications - The acquisition is expected to create significant synergies by integrating resources in R&D, production, and sales, thereby strengthening the company's global competitiveness in cardiac treatment [1] - Post-acquisition, the target group will become a wholly-owned subsidiary of the company, with its financial performance consolidated into the company's results [1] Group 3: Shareholder Impact - The transaction requires approval from a special shareholder meeting and other conditions to be met [1] - MicroPort Medical, the controlling shareholder, currently holds approximately 46.12% of the company and will see its stake reduced to about 44.45% post-transaction, remaining the largest shareholder [1]